Table 2.
Impact of enhancement on the number of cancer cases and relative increase (%) among Aboriginal people by demographic and cancer characteristics, 2010–2014
| NSWCR a | Ever reported | Most recent record | Weight of evidence | Multi-stage median | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | Increase (%) b | n | % | Increase (%) b | n | % | Increase (%) b | n | % | Increase (%) b | |
| Sex | ||||||||||||||
| Female | 1329 | 1.5 | 1920 | 2.1 | 44.5% | 1575 | 1.7 | 18.5% | 1689 | 1.9 | 27.1% | 1701 | 1.9 | 28.0% |
| Male | 1374 | 1.2 | 2264 | 2.0 | 64.8% | 1682 | 1.5 | 22.4% | 1891 | 1.7 | 37.6% | 1882 | 1.6 | 37.0% |
| Age at diagnosis | ||||||||||||||
| 0–14 | 49 | 4.4 | 61 | 5.5 | 24.5% | 54 | 4.9 | 10.2% | 57 | 5.1 | 16.3% | 56 | 5.1 | 14.3% |
| 15–24 | 47 | 3.0 | 68 | 4.4 | 44.7% | 61 | 3.9 | 29.8% | 62 | 4.0 | 31.9% | 64 | 4.1 | 36.2% |
| 25–34 | 86 | 2.0 | 143 | 3.4 | 66.3% | 120 | 2.8 | 39.5% | 128 | 3.0 | 48.8% | 130 | 3.0 | 51.2% |
| 35–44 | 224 | 2.2 | 322 | 3.2 | 43.8% | 276 | 2.8 | 23.2% | 289 | 2.9 | 29.0% | 293 | 2.9 | 30.8% |
| 45–54 | 521 | 2.2 | 727 | 3.0 | 39.5% | 627 | 2.6 | 20.3% | 661 | 2.8 | 26.9% | 675 | 2.8 | 29.6% |
| 55–64 | 714 | 1.6 | 1076 | 2.4 | 50.7% | 867 | 1.9 | 21.4% | 949 | 2.1 | 32.9% | 945 | 2.1 | 32.4% |
| 65–74 | 660 | 1.2 | 1058 | 1.9 | 60.3% | 785 | 1.4 | 18.9% | 878 | 1.6 | 33.0% | 876 | 1.6 | 32.7% |
| 75–84 | 332 | 0.8 | 570 | 1.3 | 71.7% | 388 | 0.9 | 16.9% | 451 | 1.0 | 35.8% | 447 | 1.0 | 34.6% |
| 85+ | 70 | 0.4 | 159 | 0.8 | 127.1% | 79 | 0.4 | 12.9% | 105 | 0.6 | 50.0% | 97 | 0.5 | 38.6% |
| Year of diagnosis | ||||||||||||||
| 2010 | 497 | 1.3 | 766 | 1.9 | 54.1% | 594 | 1.5 | 19.5% | 664 | 1.7 | 33.6% | 661 | 1.7 | 33.0% |
| 2011 | 532 | 1.3 | 830 | 2.1 | 56.0% | 639 | 1.6 | 20.1% | 704 | 1.7 | 32.3% | 705 | 1.7 | 32.5% |
| 2012 | 535 | 1.3 | 836 | 2.0 | 56.3% | 646 | 1.6 | 20.7% | 710 | 1.7 | 32.7% | 712 | 1.7 | 33.1% |
| 2013 | 569 | 1.4 | 851 | 2.0 | 49.6% | 683 | 1.6 | 20.0% | 745 | 1.8 | 30.9% | 747 | 1.8 | 31.3% |
| 2014 | 570 | 1.4 | 901 | 2.1 | 58.1% | 695 | 1.7 | 21.9% | 757 | 1.8 | 32.8% | 758 | 1.8 | 33.0% |
| Clinical cancer group | ||||||||||||||
| Skin | 91 | 0.4 | 284 | 1.3 | 212.1% | 177 | 0.8 | 94.5% | 212 | 1.0 | 133.0% | 216 | 1.0 | 137.4% |
| Head and neck | 145 | 2.6 | 205 | 3.6 | 41.4% | 171 | 3.0 | 17.9% | 186 | 3.3 | 28.3% | 184 | 3.2 | 26.9% |
| Upper gastrointestinal | 340 | 2.1 | 442 | 2.7 | 30.0% | 367 | 2.3 | 7.9% | 394 | 2.4 | 15.9% | 392 | 2.4 | 15.3% |
| Colorectal | 299 | 1.2 | 442 | 1.8 | 47.8% | 356 | 1.4 | 19.1% | 385 | 1.5 | 28.8% | 379 | 1.5 | 26.8% |
| Respiratory | 430 | 2.2 | 553 | 2.8 | 28.6% | 464 | 2.4 | 7.9% | 508 | 2.6 | 18.1% | 502 | 2.6 | 16.7% |
| Bone and connective tissue | 25 | 1.7 | 34 | 2.3 | 36.0% | 29 | 2.0 | 16.0% | 32 | 2.2 | 28.0% | 33 | 2.2 | 32.0% |
| Breast | 314 | 1.2 | 472 | 1.9 | 50.3% | 391 | 1.5 | 24.5% | 413 | 1.6 | 31.5% | 420 | 1.7 | 33.8% |
| Gynaecological | 179 | 2.1 | 249 | 2.9 | 39.1% | 207 | 2.4 | 15.6% | 222 | 2.6 | 24.0% | 223 | 2.6 | 24.6% |
| Urogenital | 416 | 0.9 | 803 | 1.8 | 93.0% | 547 | 1.2 | 31.5% | 627 | 1.4 | 50.7% | 633 | 1.4 | 52.2% |
| Eye and neurological | 45 | 1.4 | 68 | 2.2 | 51.1% | 51 | 1.6 | 13.3% | 56 | 1.8 | 24.4% | 57 | 1.8 | 26.7% |
| Thyroid and other endocrine | 64 | 1.2 | 109 | 2.1 | 70.3% | 81 | 1.5 | 26.6% | 93 | 1.8 | 45.3% | 94 | 1.8 | 46.9% |
| Lymphohaematopoietic | 258 | 1.2 | 401 | 1.9 | 55.4% | 313 | 1.5 | 21.3% | 344 | 1.6 | 33.3% | 343 | 1.6 | 32.9% |
| Ill-defined and unknown primary sites | 97 | 1.9 | 122 | 2.3 | 25.8% | 103 | 2.0 | 6.2% | 108 | 2.1 | 11.3% | 107 | 2.1 | 10.3% |
| Degree of spread | ||||||||||||||
| Localised | 819 | 1.0 | 1467 | 1.8 | 79.1% | 1086 | 1.3 | 32.6% | 1209 | 1.5 | 47.6% | 1212 | 1.5 | 48.0% |
| Regional | 668 | 1.5 | 964 | 2.2 | 44.3% | 767 | 1.8 | 14.8% | 857 | 2.0 | 28.3% | 850 | 2.0 | 27.2% |
| Distant | 661 | 2.2 | 783 | 2.6 | 18.5% | 686 | 2.3 | 3.8% | 713 | 2.3 | 7.9% | 713 | 2.3 | 7.9% |
| Unknown | 555 | 1.1 | 970 | 2.0 | 74.8% | 718 | 1.5 | 29.4% | 801 | 1.6 | 44.3% | 808 | 1.7 | 45.6% |
| Remoteness | ||||||||||||||
| Major Cities | 1206 | 0.9 | 1998 | 1.4 | 65.7% | 1472 | 1.1 | 22.1% | 1639 | 1.2 | 35.9% | 1633 | 1.2 | 35.4% |
| Inner Regional | 831 | 1.7 | 1277 | 2.6 | 53.7% | 1001 | 2.0 | 20.5% | 1098 | 2.2 | 32.1% | 1109 | 2.2 | 33.5% |
| Outer Regional | 530 | 3.4 | 738 | 4.7 | 39.2% | 620 | 4.0 | 17.0% | 678 | 4.3 | 27.9% | 675 | 4.3 | 27.4% |
| Remote/ very remote | 136 | 12.7 | 171 | 15.9 | 25.7% | 164 | 15.3 | 20.6% | 165 | 15.4 | 21.3% | 166 | 15.5 | 22.1% |
| Socio-economic disadvantage quintilec | ||||||||||||||
| Q1: Least disadvantaged | 131 | 0.3 | 280 | 0.7 | 113.7% | 157 | 0.4 | 19.8% | 194 | 0.5 | 48.1% | 195 | 0.5 | 48.9% |
| Q2 | 352 | 0.9 | 596 | 1.6 | 69.3% | 441 | 1.1 | 25.3% | 487 | 1.3 | 38.4% | 485 | 1.3 | 37.8% |
| Q3 | 474 | 1.1 | 785 | 1.9 | 65.6% | 580 | 1.4 | 22.4% | 650 | 1.6 | 37.1% | 654 | 1.6 | 38.0% |
| Q4 | 843 | 1.8 | 1219 | 2.6 | 44.6% | 1004 | 2.2 | 19.1% | 1082 | 2.3 | 28.4% | 1087 | 2.3 | 28.9% |
| Q5: Most disadvantaged | 903 | 2.4 | 1304 | 3.4 | 44.4% | 1075 | 2.8 | 19.0% | 1167 | 3.1 | 29.2% | 1162 | 3.1 | 28.7% |
aNSWCR: Aboriginal status variable in the NSW Cancer Registry
bRelative increase compared with the number of cases based on the NSW Cancer Registry Aboriginal status variable
cIndex of Relative Socio-economic Disadvantage